ClinicalTrials.gg
RecruitingNCT06488287Updated Jul 5, 2024

tDCS and Emotional Eating

An interventional study of Transcranial direct current stimulation (brain stimulation) and sham Transcranial direct current stimulation (brain stimulation) in Eating Disorders, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by University of Nottingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Feb 2024, registered May 2024).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Feeding and Eating Disorders with a site in United Kingdom — 5 open to participants now, 7 under way, none of them phase 3. Feeding and Eating Disorders · United Kingdom.

Planned enrollment
13th of 20
30 · median 45
Started
2024
with 3 others
No phase
18 of 28
2 open now
Registered
22nd of 28
by date

Among the 28 studies in Feeding and Eating Disorders with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2024, is one of 18 with no phase, and was the 22nd registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

5 of the 28 studies in Feeding and Eating Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Feeding and Eating Disorders with a site in United Kingdom, or all of them as a file.
02

Study summary

This research investigates the feasibility of undertaking a large, randomised control trial of transcranial direct current stimulation (tDCS) as a treatment modality for managing food cravings and emotional eating. This study explores how tDCS, a non-invasive brain stimulation technique, can influence brain activity and potentially impact appetite regulation, self-control, reward processing, and other factors related to weight management.

All participants will receive 6 sessions of stimulation within three weeks. the investigators aim to implement a two-day interval between intervention sessions, providing participants with a two-day rest period between sessions. This scheduling approach is intended to mitigate potential side effects and promote participants' recovery.

Read the detailed description

Participants were invited to take part in this study based on their registration in the tier 3 bariatric service at the Royal Derby Hospital and a score of more than 6 in the binge eating survey previously completed as part of their clinical care. the invistigators invite 30-40 participants to participate in this study.

After the completion of the consent form participants will be asked to complete a safety questionnaire to check whether there are any known reasons tDCS would not be suitable for them. If it is suitable to participate in a tDCS study for obesity, participants will be randomised to either real tDCS or Sham tDCS (Sham tDCS is like a "fake" version of tDCS. It's used in experiments to make people think they're getting brain stimulation when they're not. This helps researchers see if the real brain stimulation has a genuine effect or if it's just because people believe it will work). The randomization process for group assignment will be conducted using a computer program, which means participants will not have the ability to select or choose their preferred group. participants will receive 6 sessions of real tDCS or sham for three weeks (2 sessions a week). the investigators will follow up with participants for two weeks after the study end. The follow-up procedure will involve the completion of questionnaires and the stop signal task once again. Additionally, body weight measurements will be taken during this stage. Therefore, they will participate for 8 weeks in this study. All sessions will take place in the University of Nottingham medical school at Derby Royal Hospital and University of Nottingham jubilee campus. The first and last session will take approximately 1.30 hours and the other sessions will last 40 minutes each. In the first and last sessions, participants will be asked to fill in 4 questionnaires (30 minutes to fill), doing an impulsivity test (also known as Stop Signal Task) (it is an easy test and will take 5 minutes. The stop signal task is a psychological test that measures participant ability to stop or pause a planned action when they're signalled to do so. It helps assess self-control and how well participants can inhibit or control their impulses) and receive one session of tDCS or sham (20 minutes). In the 4 sessions, the participant will only receive one session of real tDCS or sham. During the study (8 weeks) the participant will be asked to fill a daily food record using mobile app. After the end of the study, the participant will be asked to do an interview to talk about the experience of being in the study. The interview will be conducted at the end of the study either in person or online using Teams.

tDCS has no major safety concerns according to National Institute for health and Care Excellence (NICE 2015). The most frequent temporary side effects are mild tingling, slight itching, moderate fatigue, headache or, less frequently, a slight burning feeling. These effects usually develop at the start of the tDCS and disappear shortly after. Headaches, mild discomfort, or irritation on the skin generally involve slight discomforts that are promptly relieved by over-the-counter pain relief medicines. It is important to inform us of any side effects experienced after the tDCS sessions and to contact participant's GP or treating clinician with any healthcare concerns or study-related questions.

the investigators cannot promise the study will help the participant but the information that investigators get from this study may help to the advancement of scientific knowledge by expanding our understanding of the effects of tDCS on appetite regulation, cognitive control, and long-term behaviour modification in the context of obesity, potentially leading to the development of more effective treatments and interventions for weight management in the future.

the recruitment started on 01/03/2024 and the study end date will be 30/09/2025. this study was funded py the PGR office at the University of Nottingham.

03

Conditions studied

  • Eating Disorders

Keywords

  • obesity
  • emotional eating
  • brain stimulation
  • tDCS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with obesity in tier 3.
  • Capacity to consent to participate in research.
  • Adults aged 18 to 65 years old.
  • A high score in the emotional eating survey (minimum of 6 score in weight loss readiness questionnaire) (this will be taken from participant's medical note by usual care staff)

Exclusion criteria

Exclusion Criteria:

  • Non-obese patients (\<25).
  • A history of epilepsy or other major neurological disorders
  • Having pacemakers or other metal implants.
  • No history of eating disorders or emotional eating.
  • Pregnant patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Real stimulation

    Participants in this arm will receive 6 sessions of real tDCS.

    Device: Transcranial direct current stimulation (brain stimulation)

  • Placebo comparator
    Sham stimulation

    Participants in this arm will receive 6 sessions of sham tDCS.

    Device: sham Transcranial direct current stimulation (brain stimulation)

Interventions

  • DeviceTranscranial direct current stimulation (brain stimulation)

    The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.

  • Devicesham Transcranial direct current stimulation (brain stimulation)

    The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.

06

What researchers measure

Primary outcomes

  1. Response rate and number of patients who met the inclusion criteria, agreed to participate in the study, and completed the study.

    Response rate and number of patients who met the inclusion criteria, agreed to participate in the study, and completed the study.

    Time frame: 5 weeks

  2. Feasibility of completion study questionnaire.

    number of patients who met the inclusion criteria, agreed to participate in the study, and completed the study questionnaire.

    Time frame: 5 weeks

  3. Means and standard deviations of scores on study questionnaires.

    3. Means and standard deviations of scores on study questionnaires.

    Time frame: 5 weeks

  4. Dropout ratio in each group

    Time frame: 5 weeks

  5. Safety of the intervention will be assessed by adverse event reported by patients

    Time frame: 5 weeks

Secondary outcomes

  1. Body weight (Kg)

    Time frame: 5 weeks

  2. BMI (kg/m^2)

    Time frame: 5 weeks

  3. The Eating Disorder Examination Questionnaire (EDE-Q)

    The Eating Disorder Examination Questionnaire (EDE-Q) is a widely used self-report measure for assessing the range and severity of eating disorder symptoms. It consists of 28 items and evaluates behaviours and attitudes associated with eating disorders over the past 28 days. The questionnaire is divided into four subscales: A global score of 2.3 is often used as a cut-off to identify probable eating disorders.

    Time frame: 5 weeks

  4. The Food Cravings Questionnaire-State (FCQ-S)

    The Food Cravings Questionnaire-State (FCQ-S) measures momentary food cravings using a 15-item scale. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). This gives the FCQ-S a minimum possible score of 15 and a maximum possible score of 75. High score means worse symptoms.

    Time frame: 5 weeks

  5. The Emotional Eating Scale II (EES-II)

    The Emotional Eating Scale II (EES-II) is an extended version of the original Emotional Eating Scale (EES), designed to assess eating in response to both positive and negative emotions. The EES-II consists of 33 items, each rated on a 5-point scale from 0 (no desire to eat) to 4 (an overwhelming urge to eat). This results in a minimum score of 0 and a maximum score of 132. The EES-II includes subscales that measure eating in response to different emotional states: Anger/Frustration (9 items) Anxiety (8 items) Depression (10 items) Positive Emotions (6 items) Higher scores on the EES-II indicate a greater tendency to eat in response to emotional states, both positive and negative.

    Time frame: 5 weeks

  6. Calories consumption (using food record app)

    Time frame: 5 weeks

  7. Impulsivity using stop signal task

    Time frame: 5 weeks

  8. Adverse events

    Time frame: 5 weeks

  9. The Food Craving Questionnaire-Trait (FCQ-T)

    The Food Craving Questionnaire-Trait (FCQ-T) assesses the frequency and intensity of food cravings over time and consists of 39 items. Each item is rated on a 6-point Likert scale, where 1 indicates "never" and 6 indicates "always." The total score ranges from a minimum of 39 to a maximum of 234. Higher scores reflect greater food craving tendencies.

    Time frame: 5 weeks

  10. The Food Craving Inventory (FCI)

    The Food Craving Inventory (FCI) is a self-report measure designed to assess the frequency of food cravings for specific food types over the past month. The FCI consists of 28 items, each rated on a 5-point scale from 1 (never) to 5 (always/almost every day). This gives the FCI a minimum possible score of 28 and a maximum possible score of 140. high score means worse symptoms.

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

Of 267 non-industry interventional studies with no phase under Feeding and Eating Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 10 months is below that.

Counting every sponsor, half of 272 studies reached it within 28 months; a quarter within 14 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
Jul 5, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Sep 30, 2025
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06488287
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Feb 1, 2024
Primary completion
Dec 31, 2024 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jul 5, 2024

Study contacts

Iskandar Idris
Contact
mdzii@exmail.nottingham.ac.uk
01332 724710/724713
yousef Alhindi
Contact
alyya2@nottingham.ac.uk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion